Materias dentro de su búsqueda.
Mostrando 1,761 - 1,780 Resultados de 1,900 Para Buscar '"AstraZeneca"', tiempo de consulta: 0.14s Limitar resultados
  1. 1761
    “…At ages 18–64 years, the adjusted vaccine effectiveness against infection was 62·8% (95% CI 49·3–72·7) after two doses compared to unvaccinated people, for all vaccines combined, 44·8% (22·5–60·7) for the ChAdOx1 nCov-19 (Oxford–AstraZeneca) vaccine, and 71·3% (56·6–81·0) for the BNT162b2 (Pfizer–BioNTech) vaccine. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    SARS-CoV-2 infection and vaccine effectiveness in England (REACT-1): a series of cross-sectional random community surveys
  2. 1762
    “…A partir de janeiro de 2021, foi iniciado a vacinação nos TAS: 70,9% vacinados com CoronaVac (Sinovac); 26,9% AstraZeneca; 0,2% Janssen; Pfizer 1,9% e 0,2% Janssen. …”
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    IMPACTO DA VACINAÇÃO E DAS MEDIDAS DE PREVENÇÃO PARA COVID-19 EM TRABALHADORES DA ÁREA DA SAÚDE DE 12 HOSPITAIS DO ESTADO DE SÃO PAULO
  3. 1763
    “…Vaccine effectiveness was calculated after primary immunization with two doses of BNT162b2 (Pfizer–BioNTech), ChAdOx1 nCoV-19 (AstraZeneca), or mRNA-1273 (Moderna) vaccine and after a booster dose of BNT162b2, ChAdOx1 nCoV-19, or mRNA-1273. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Covid-19 Vaccine Effectiveness against the Omicron (B.1.1.529) Variant
  4. 1764
    por Liu, Xinxue, Munro, Alasdair P S, Feng, Shuo, Janani, Leila, Aley, Parvinder K, Babbage, Gavin, Baxter, David, Bula, Marcin, Cathie, Katrina, Chatterjee, Krishna, Dejnirattisai, Wanwisa, Dodd, Kate, Enever, Yvanne, Qureshi, Ehsaan, Goodman, Anna L., Green, Christopher A, Harndahl, Linda, Haughney, John, Hicks, Alexander, van der Klaauw, Agatha A., Kwok, Jonathan, Libri, Vincenzo, Llewelyn, Martin J, McGregor, Alastair C, Minassian, Angela M., Moore, Patrick, Mughal, Mehmood, Mujadidi, Yama F, Holliday, Kyra, Osanlou, Orod, Osanlou, Rostam, Owens, Daniel R, Pacurar, Mihaela, Palfreeman, Adrian, Pan, Daniel, Rampling, Tommy, Regan, Karen, Saich, Stephen, Serafimova, Teona, Saralaya, Dinesh, Screaton, Gavin R, Sharma, Sunil, Sheridan, Ray, Sturdy, Ann, Supasa, Piyada, Thomson, Emma C, Todd, Shirley, Twelves, Chris, Read, Robert C., Charlton, Sue, Hallis, Bassam, Ramsay, Mary, Andrews, Nick, Lambe, Teresa, Nguyen-Van-Tam, Jonathan S, Cornelius, Victoria, Snape, Matthew D, Faust, Saul N
    Publicado 2022
    “…In the participants who had two initial doses of ChAdOx1 nCov-19 (Oxford-AstraZeneca; hereafter referred to as ChAd), schedules using mRNA vaccines as third dose have the highest anti-spike IgG at D84 (e.g. geometric mean concentration of 8674 ELU/ml (95% CI: 7461–10,085) following ChAd/ChAd/BNT162b2 (Pfizer-BioNtech, hearafter referred to as BNT)). …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Persistence of immunogenicity after seven COVID-19 vaccines given as third dose boosters following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK: Three month analyses of the COV-BOOST trial.
  5. 1765
    “…DISCLOSURES: Phillips:Karyopharm: Consultancy; AstraZeneca: Consultancy; Beigene: Consultancy; Abbvie: Consultancy, Research Funding; Pharmacyclics: Consultancy; Bayer: Consultancy, Research Funding; BMS: Consultancy; Incyte: Consultancy, Other: travel expenses; Seattle Genetics: Consultancy; Cardinal Health: Consultancy.…”
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    The Feasibility of Virtual Toxicity Assessments in Lymphoma Patients Receiving Immunochemotherapy
  6. 1766
    “…FUNDING: This study was funded between AstraZeneca CRUK, National Cancer Research Institute, and Cancer Research UK Feasibility Study Committee.…”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Olaparib maintenance versus placebo monotherapy in patients with advanced non-small cell lung cancer (PIN): A multicentre, randomised, controlled, phase 2 trial
  7. 1767
    “…We aimed to assess the safety and immunogenicity of primary vaccination with VLA2001 versus the ChAdOx1-S (Oxford-AstraZeneca) adenoviral-vectored vaccine. METHODS: In this immunobridging phase 3 trial (COV-COMPARE), participants aged 18 years and older who were medically stable (as determined by an investigator) were enrolled at 26 sites in the UK. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Immunogenicity and safety of an inactivated whole-virus COVID-19 vaccine (VLA2001) compared with the adenoviral vector vaccine ChAdOx1-S in adults in the UK (COV-COMPARE): interim analysis of a randomised, controlled, phase 3, immunobridging trial
  8. 1768
    “…Pts not seroconverted after 4-5 doses of vaccine received tixagevimab/cilgavimab (EVUSHELD®, AstraZeneca). Tolerance using telemedicine application. …”
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    REAL-LIFE STUDY OF BIO-CLINICAL FOLLOW-UP AFTER BNT162b2 mRNA COVID-19 (BNTCV) VACCINATION IN 235 PATIENTS (PTS) INCLUDING 225 WITH HEMATOLOGICAL MALIGNANCIES (HM).
  9. 1769
    “…To investigate this hypothesis, we tested for presence of combined IgG, IgA and IgM (IgGAM) anti-Spike antibodies before and after 2 doses of ChAdOx1 nCoV-19 (ChAdOx1, AstraZeneca) or BNT162b2 (Pfizer-BioNTech) in UK adults participating in a population-based longitudinal study who received their first dose of vaccine between December 2020 and July 2021. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Determinants of Antibody Responses to SARS-CoV-2 Vaccines: Population-Based Longitudinal Study (COVIDENCE UK)
  10. 1770
    “…Methods: We investigated the levels of anti-SARS-CoV-2 antibodies (IgG) and neutralizing antibodies (NAbs) in 195 healthy adult subjects belonging to the staff of the University-Hospital of Ferrara (Italy) starting from 15 days up to 190 days (about 6 months) after the second dose of the BNT162b2 (Pfizer–BioNTech) mRNA-based vaccine (n = 128) or ChAdOx1 (AstraZeneca) adenovirus-based vaccine (n = 67) using a combined approach of serological and genomics investigations. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Host genetics impact on SARS-CoV-2 vaccine-induced immunoglobulin levels and dynamics: The role of TP53, ABO, APOE, ACE2, HLA-A, and CRP genes
  11. 1771
    “…Arendrup, DMSci, PhD, MD, Chiesi, Gilead: Honoraria|F2G, Cidara, Scynexis: Grant/Research Support Michael Perch, MD, Boeringer-Ingelheim: Travel grant|PulmonX: Expert Testimony|Roche: Grant/Research Support|Takeda: Expert Testimony|Therakos: Honoraria|Zambon: Advisor/Consultant|Zambon: Expert Testimony Marie Helleberg, PhD, DMSc, AstraZeneca: Advisor/Consultant|Gilead: Advisor/Consultant|Gilead: Honoraria|GSK: Advisor/Consultant|GSK: Honoraria|Janssen: Advisor/Consultant|Roche: Advisor/Consultant|Sobi: Advisor/Consultant.…”
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    82. Incidence rates of invasive aspergillosis among lung transplant recipients in timeperiods with universal and targeted antifungal prophylaxis - a nationwide cohort study
  12. 1772
    “…FUNDING: NIBIT Foundation, Fondazione AIRC, AstraZeneca.…”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Tremelimumab plus durvalumab retreatment and 4-year outcomes in patients with mesothelioma: a follow-up of the open label, non-randomised, phase 2 NIBIT-MESO-1 study
  13. 1773
    “…The RSC captured vaccine coverage data for influenza (n=5.4 million) and COVID-19, reporting dose one (n=11.9 million), two (n=11 million), and three (n=0.4 million) for the latter as well as brand-specific uptake data (AstraZeneca vaccine, n=11.6 million; Pfizer, n=10.8 million; and Moderna, n=0.7 million). …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Representativeness, Vaccination Uptake, and COVID-19 Clinical Outcomes 2020-2021 in the UK Oxford-Royal College of General Practitioners Research and Surveillance Network: Cohort Profile Summary
  14. 1774
    “…FUNDING: International Union Against Tuberculosis and Lung Disease, Boehringer Ingelheim New Zealand, AstraZeneca, UK National Institute for Health Research, UK Medical Research Council, European Research Council, the Spanish Instituto de Salud Carlos III. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Asthma management and control in children, adolescents, and adults in 25 countries: a Global Asthma Network Phase I cross-sectional study
  15. 1775
    “…BACKGROUND: Both BNT162b2 (Pfizer–BioNTech) and ChAdOx1 nCoV-19 (Oxford–AstraZeneca) vaccines have shown high efficacy against COVID-19 in randomized controlled trials. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Comparative effectiveness of BNT162b2 and ChAdOx1 nCoV-19 vaccines against COVID-19
  16. 1776
    “….: Support for the present publication|AstraZeneca: Advisor/Consultant|AstraZeneca: Grant/Research Support|DiaSorin Molecular LLC: Advisor/Consultant|Eli Lilly and Company: Grant/Research Support|Enanta Pharmaceuticals: Grant/Research Support|F. …”
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    1699. Safety and Outcomes of Isavuconazonium Sulfate for the Treatment of Invasive Aspergillosis or Invasive Mucormycosis in Pediatric Patients
  17. 1777
    por Liu, Xinxue, Munro, Alasdair P S, Wright, Annie, Feng, Shuo, Janani, Leila, Aley, Parvinder K, Babbage, Gavin, Baker, Jonathan, Baxter, David, Bawa, Tanveer, Bula, Marcin, Cathie, Katrina, Chatterjee, Krishna, Dodd, Kate, Enever, Yvanne, Fox, Lauren, Qureshi, Ehsaan, Goodman, Anna L., Green, Christopher A, Haughney, John, Hicks, Alexander, Jones, Christine E, Kanji, Nasir, van der Klaauw, Agatha A., Libri, Vincenzo, Llewelyn, Martin J, Mansfield, Rebecca, Maallah, Mina, McGregor, Alastair C, Minassian, Angela M., Moore, Patrick, Mughal, Mehmood, Mujadidi, Yama F, Belhadef, Hanane Trari, Holliday, Kyra, Osanlou, Orod, Osanlou, Rostam, Owens, Daniel R, Pacurar, Mihaela, Palfreeman, Adrian, Pan, Daniel, Rampling, Tommy, Regan, Karen, Saich, Stephen, Saralaya, Dinesh, Sharma, Sunil, Sheridan, Ray, Stokes, Matthew, Thomson, Emma C, Todd, Shirley, Twelves, Chris, Read, Robert C., Charlton, Sue, Hallis, Bassam, Ramsay, Mary, Andrews, Nick, Lambe, Teresa, Nguyen-Van-Tam, Jonathan S, Cornelius, Victoria, Snape, Matthew D, Faust, Saul N
    Publicado 2023
    “…The trial was stratified such that half of participants had previously received two primary doses of ChAdOx1 nCov-19 (Oxford–AstraZeneca; hereafter referred to as ChAd) and half had received two doses of BNT162b2 (Pfizer–BioNtech, hereafter referred to as BNT). …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Persistence of immune responses after heterologous and homologous third COVID-19 vaccine dose schedules in the UK: eight-month analyses of the COV-BOOST trial
  18. 1778
    “…Research Investigator; Self; Abbott Laboratories, Agios Pharmaceuticals, Alexion Pharmaceuticals, Inc., Alnylam, Amgen Inc, Angionetics, Anthos Therapeutics, ARCA Biopharma Inc, Array, AstraZeneca, Atentiv, Better Therapeutics, Bayer, Inc., Bristol-Myers Squibb, Cardiol Therapeutics, CellResearch Corp, CSL Behring, Eidos Therapeutics, EP Trading Company, Esperion Therapeutics, EveryWell, Faraday Pharmaceuticals, Fortress Biotech, HeartFlow, Insmed, Jansen Pharmaceuticals, Lexicon Pharmaceuticals, Inc., Kowa Research, Merck & Co., Moderna, Novo Nordisk, Pfizer, Inc., PhaseBio, PPD Development, Prothena Biosciences, Regeneron Pharmaceuticals, Regio Biosciences, Sanifit Therapeutics, Sanofi, Stealth Biotherapeutics, Wraser, Cambrian Biopharma, Cook Regentech, EPG Communications, Epizon Pharma, Exicon Consulting, Medtronic, Silence Therapeutics, VarmX. …”
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    THU254 VICTOR-Pilot Study Of A Virtual Dietary Intervention To Improve Diabetes And Cardiovascular Risk In Rural Communities - Primary Results
  19. 1779
    “…Research Investigator; Self; Akcea Therapeutics, Amgen Inc, Amryt, AstraZeneca, Ionis Pharmaceuticals Inc., Novartis Pharmaceuticals, Regeneron Pharmaceuticals, RegenXBio. …”
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    FRI090 Patterns Of Triglyceride Testing And Results Over Time Among Patients With Diabetes And Severe Hypertriglyceridemia In US Clinical Practice
  20. 1780
    “…Serretti Consultant of: Abbott, Abbvie, Angelini, AstraZeneca, Clinical Data, Boehringer, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Innovapharma, Italfarmaco, Janssen, Lundbeck, Naurex, Pfizer, Polifarma, Sanofi, Servier, and Taliaz, J. …”
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Is emotion dysregulation correlated to depressive and manic symptoms of bipolar disorder? Results from a systematic review and network meta-analysis
Herramientas de búsqueda: RSS